These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 22001159)

  • 1. Stress, depression and Parkinson's disease.
    Hemmerle AM; Herman JP; Seroogy KB
    Exp Neurol; 2012 Jan; 233(1):79-86. PubMed ID: 22001159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Life Stress, Depression And Parkinson's Disease: A New Approach.
    Dallé E; Mabandla MV
    Mol Brain; 2018 Mar; 11(1):18. PubMed ID: 29551090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Depression in Parkinson's disease. Part 1: epidemiology, signs and symptoms, pathophysiology and diagnosis].
    Storch A; Ebersbach G; Fuchs G; Jost WH; Odin P; Reifschneider G; Bauer M
    Fortschr Neurol Psychiatr; 2008 Dec; 76(12):715-24. PubMed ID: 19012223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can stress trigger Parkinson's disease?
    Djamshidian A; Lees AJ
    J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):878-81. PubMed ID: 24259593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders.
    Walter U; Hoeppner J; Prudente-Morrissey L; Horowski S; Herpertz SC; Benecke R
    Brain; 2007 Jul; 130(Pt 7):1799-807. PubMed ID: 17329323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal Change of DAT SPECT in Parkinson's Disease and Multiple System Atrophy.
    Sakakibara S; Hashimoto R; Katayama T; Kenjyo M; Yokokawa Y; Saito Y; Hirakawa A; Ito M; Nakamura T; Hara K; Hashizume A; Aiba I; Inukai A; Katsuno M
    J Parkinsons Dis; 2020; 10(1):123-130. PubMed ID: 31707374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nigrostriatal interaction in the aging brain: new therapeutic target for Parkinson's disease.
    Błaszczyk JW
    Acta Neurobiol Exp (Wars); 2017; 77(1):106-112. PubMed ID: 28379221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Shin E; Rogers JT; Devoto P; Björklund A; Carta M
    Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence, etiology, and treatment of depression in Parkinson's disease.
    McDonald WM; Richard IH; DeLong MR
    Biol Psychiatry; 2003 Aug; 54(3):363-75. PubMed ID: 12893111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic mild stress accelerates the progression of Parkinson's disease in A53T α-synuclein transgenic mice.
    Wu Q; Yang X; Zhang Y; Zhang L; Feng L
    Exp Neurol; 2016 Nov; 285(Pt A):61-71. PubMed ID: 27637804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Depression in Parkinson's disease].
    Kitamura S; Nagayama H
    Seishin Shinkeigaku Zasshi; 2013; 115(11):1135-41. PubMed ID: 24450146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The degeneration of dopamine neurons in Parkinson's disease: insights from embryology and evolution of the mesostriatocortical system.
    Vernier P; Moret F; Callier S; Snapyan M; Wersinger C; Sidhu A
    Ann N Y Acad Sci; 2004 Dec; 1035():231-49. PubMed ID: 15681811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the loss of thalamostriatal neurons protective in parkinsonism?
    Kusnoor SV; Muly EC; Morgan JI; Deutch AY
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3(Suppl 3):S162-6. PubMed ID: 20082981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What a neurologist should know about depression in Parkinson's disease.
    Timmer MHM; van Beek MHCT; Bloem BR; Esselink RAJ
    Pract Neurol; 2017 Oct; 17(5):359-368. PubMed ID: 28739866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
    Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
    Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apathy in untreated early-stage Parkinson disease: relationship with other non-motor symptoms.
    Dujardin K; Langlois C; Plomhause L; Carette AS; Delliaux M; Duhamel A; Defebvre L
    Mov Disord; 2014 Dec; 29(14):1796-801. PubMed ID: 25370724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restorative strategies for the dopaminergic nigrostriatal projection pathway.
    Nikkhah G
    Acta Neurochir Suppl; 2013; 117():79-85. PubMed ID: 23652661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Depression in Parkinson's disease].
    Kamrowska A
    Pol Merkur Lekarski; 2009 Aug; 27(158):170-2. PubMed ID: 19856889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of the prevalence and etiology of depression in Parkinson's disease.
    Habermann-Little B
    J Neurosci Nurs; 1991 Jun; 23(3):165-9. PubMed ID: 1831481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical issues in the treatment of anxiety and depression in older adults with Parkinson's disease.
    Pachana NA; Egan SJ; Laidlaw K; Dissanayaka N; Byrne GJ; Brockman S; Marsh R; Starkstein S
    Mov Disord; 2013 Dec; 28(14):1930-4. PubMed ID: 24123116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.